Attract what matters.
Enzyme solutions for PCR, Real-Time PCR,
and Next-Generation Sequencing.
NGS library preparation. Evolved.
Evolved to Focus.
your qPCR inhibitions
This research provides a quantitative comparison of different commercially available library kits in regards to minimal bias, yield and time efficiency. Each library preparation kit was tested by starting with the same DNA sample and by probing the amount of DNA remaining after each protocol step. The results show that the kits that combine several steps, such as KAPA HyperPlus and KAPA Hyper Prep kits, exhibit some yields 4 to 7 times higher than other kits. Read more
The KAPA Hyper PCR-free system appears to be the best solution for specimens in which ∼500 ng of high-quality DNA is available for library preparation.
Learn how the Hyper Prep Kit and Kapa HiFi Uracil PCR Polymerase were used to evaluate whether CpG methylation of transposable elements are associated with anaplastic lymphoma kinase expression in cancer.
This paper provide a detailed molecular analysis of the spatial heterogeneity of clinically localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors.
Researchers at Foundation Medicine have created a test to interrogate base substitutions, indels, copy number alterations and selected fusions across 287 cancer related genes from FFPE tumor samples using massively parallel next generation sequencing.
Researchers at the Broad Institute evaluate four sequencing platforms using human and microbial samples to assess sources of bias in sequencing and sample preparation workflow processes.
Researchers at the Sanger Center investigate many thermostable DNA polymerases along with various reaction conditions for adapter-ligated fragments for Illumina Sequencing in efforts to determine and reduce bias.
We are pleased to share that today we officially became part of the Roche Group, in an exciting partnership that will accelerate our ability to pioneer new technologies and expand our product portfolio. (Read the full announcement). This deal closed today, and for the immediate future there will be no changes to our account teams, or your contacts for product services and support issues. We look forward to sharing more information with you as our integration plans get underway.